What is Gelomics?
Gelomics operates at the intersection of biotechnology and advanced materials science, specializing in the rapid development of accurate 3D tissue models. Central to its value proposition is the proprietary LunaX Photocrosslinking Technology, which enables researchers to create biologically relevant environments that mimic human physiology with unprecedented precision. By serving academic institutions, pharmaceutical giants, and contract research organizations, the company addresses the urgent need for more predictive models in drug discovery and disease research.
The firm's commitment to reliability and reproducibility positions it as a key player in the transition toward personalized medicine. By providing tools that reduce the reliance on traditional, less accurate testing methods, Gelomics is effectively lowering the barrier to entry for high-throughput screening and complex therapeutic development.
How much funding has Gelomics raised?
Gelomics has raised a total of $2.2M across 1 funding round:
Other Financing Round
$2.2M
Other Financing Round (2024): $2.2M with participation from Jelix Ventures and QIC
Key Investors in Gelomics
Jelix Ventures
Jelix Ventures is an early-stage venture capital firm that supports bold founders in Australia and New Zealand, focusing on innovative startups that aim to create a better future.
QIC
QIC is a leading long-term specialist investment manager that provides strategic capital and financial expertise to support high-growth enterprises.
What's next for Gelomics?
With this major enterprise-level funding, Gelomics is poised to transition from a specialized technology provider to a foundational infrastructure partner in the life sciences sector. The strategic roadmap likely includes the expansion of its product portfolio to support broader therapeutic areas and the enhancement of its manufacturing capabilities to meet rising global demand.
Future growth will be driven by the integration of its 3D cell culture systems into standard pharmaceutical workflows, potentially shortening the drug development lifecycle. As the company scales, it will likely focus on strategic partnerships that leverage its LunaX technology to solve persistent challenges in oncology, neurology, and regenerative medicine, ultimately cementing its role as a leader in the next generation of biomedical research tools.
